2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
3
Study Type
Observational
3
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Breast
1
Conditions
Drug-Related Side Effects and Adverse Reactions
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Breast Neoplasms
1
Interventions
Surveys and Questionnaires
543
Blood Specimen Collection
446
Surgical Procedures, Operative
164
Observation
152
Drug Therapy
142
Radiotherapy
141
Interviews as Topic
139
Gene Expression Profiling
129
Biopsy
117
Magnetic Resonance Spectroscopy
116
Immunohistochemistry
112
Data Collection
95
Polymerase Chain Reaction
87
Specimen Handling
81
Amplified Fragment Length Polymorphism Analysis
81
Bevacizumab
78
Microarray Analysis
76
Flow Cytometry
69
Neoadjuvant Therapy
68
Watchful Waiting
66
Magnetic Resonance Imaging
65
Immune Checkpoint Inhibitors
61
Nivolumab
60
Immunotherapy
57
Therapeutics
55
Reverse Transcriptase Polymerase Chain Reaction
52
pembrolizumab
50
Ultrasonography
47
Positron Emission Tomography Computed Tomography
47
Hematologic Tests
46
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Observational
×
Social Determinants of Health
×
Clear all
NCT05096338
2026-03-23
PCT
Abramson Cancer Center at Penn Medicine
Active not recruiting
200 enrolled
NCT05078190
2025-11-06
CCT2
Abramson Cancer Center at Penn Medicine
Active not recruiting
200 enrolled
NCT06081517
2025-06-13
EDPO
Indiana University
Recruiting
10,600 enrolled